Cytarabine

Evidence Level: L4

Predicted Indications: 9

Cytarabine

Pharmacist Assessment Report

Cytarabine: From Acute Leukemia to Small Cell Lung Carcinoma

One-Sentence Summary

Cytarabine is a pyrimidine nucleoside antimetabolite chemotherapy, originally used to treat acute lymphoblastic and acute myeloid leukemias. The TxGNN model predicts it may be effective for small cell lung carcinoma, but there are no registered clinical trials and only indirect, mostly historical literature (about 20 publications, largely on non-small cell lung cancer), so the evidence is weak.

Quick Overview

Item	Content
Original Indication	Acute lymphoblastic leukemia and acute myeloid leukemia (including several AML subtypes). Health Canada indication text is not available in the data compiled for this report.
Predicted New Indication	Small cell lung carcinoma
TxGNN Prediction Score	0.9978
Evidence Level	L4
Canada Market Status	Marketed (marketed DINs: 4 of 4)
Number of DINs	4 (marketed: 4)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the compiled data. Based on general pharmacology, cytarabine is a pyrimidine nucleoside analog that inhibits DNA synthesis in S-phase cells. Its efficacy in acute leukemias is well established, and mechanistically it could be applicable to other rapidly proliferating tumors.

Small cell lung carcinoma is a fast-growing malignancy, which gives the prediction a plausible biological rationale. However, the retrieved literature mostly concerns non-small cell lung cancer (phase II cytarabine plus cisplatin studies from 1990) and general antimetabolite reviews. No SCLC-specific cytarabine study with a clear result was identified beyond a 1987 report titled “High-dose cytarabine in small cell lung cancer” (no abstract available). Solid tumors are also generally less sensitive to cytarabine than leukemias. The evidence is therefore indirect and historical.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2156598	1990	Phase II trial	Cancer	High-dose cytarabine plus cisplatin in 37 untreated NSCLC patients: overall response rate 14%; grade IV myelosuppression in 32%; 4 deaths on study
2157307	1990	Phase II trial	Tumori	Cisplatin, vindesine and low-dose cytarabine in 32 patients with advanced NSCLC; modest activity reported
2158614	1990	Randomized phase II	Med Pediatr Oncol	CALGB trial of cisplatin-cytarabine vs cisplatin-vinblastine in 151 NSCLC patients
2820740	1987	Pilot study	Eur J Cancer Clin Oncol	Cisplatin plus cytarabine combination in advanced NSCLC
3030547	1987	Clinical report	Cancer Treat Rep	High-dose cytarabine in small cell lung cancer (no abstract available)
1360876	1992	Preclinical	Cancer Chemother Pharmacol	Drug sensitivity patterns in SCLC cell lines (doxorubicin, etoposide, vincristine, carmustine)
22836285	2012	Review	Curr Treat Options Oncol	Treatment of leptomeningeal spread of NSCLC
28223673	2017	Case report	Gan To Kagaku Ryoho	SCLC with meningeal carcinomatosis treated with a multidisciplinary approach
1332622	1992	Review	Gan To Kagaku Ryoho	Gemcitabine and DMDC, antimetabolites structurally related to cytarabine
18600541	2008	Preclinical	Nucleosides Nucleotides Nucleic Acids	Nucleoside transporters hENT1/hCNT1 expressed in NSCLC cell lines and patient samples

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02406772	PMS-CYTARABINE	Not available	Not available
02126656	CYTARABINE INJECTION	Not available	Not available
02515296	CYTARABINE INJECTION	Not available	Not available
02515490	VYXEOS	Not available	Not available

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (pyrimidine nucleoside antimetabolite)
Myelosuppression Risk	High (the NSCLC phase II study reported grade IV myelosuppression in 32% of patients)
Emetogenicity Classification	Nausea and vomiting reported in the high-dose setting; please refer to the package insert
Monitoring Items	Complete blood count with differential, liver and renal function
Handling Protection	Must follow cytotoxic drug handling regulations

Safety Considerations

Disease-based cautions (knowledge graph, not label text): The drug is linked to contraindication relationships with kidney disease, liver disease, pancreatitis, gallbladder disease, thrombocytopenia, anemia, leukopenia, neutropenia and agranulocytosis (including congenital neutropenia syndromes), peripheral neuropathy, pulmonary edema, diarrheal disease, necrotizing enterocolitis, and fungal infections.
Drug Interactions: 100 interactions were found. Among those listed, naltrexone is rated Moderate and levofloxacin Minor. Other listed interactions (for example mannitol, pantoprazole, metformin, morphine, prednisone, simvastatin) have an unknown severity rating.

Please also refer to the package insert for official warnings and contraindications, which were not available in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction score is very high, but it is not backed by any registered trial or direct SCLC clinical evidence. The retrieved studies are old, mostly in NSCLC, and showed modest response with substantial myelosuppression. Cytarabine is already marketed in Canada, so access is not a barrier; the evidence is.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
Mechanism of action data (for example from DrugBank)
A focused review of SCLC-specific cytarabine data, including the 1987 high-dose cytarabine report
Preclinical or early clinical data in SCLC to support a registered trial
Approved indication text, dosage forms and manufacturer details for the Canadian licences
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.